Site-Specific Conjugation of Boron-Containing Dendrimers to Anti-EGF Receptor Monoclonal Antibody Cetuximab (IMC-C225) and Its Evaluation as a Potential Delivery Agent for Neutron Capture Therapy

Bioconjugate Chemistry

Volumn 15, Issue 1, 2004, Pages 185-194

  Wu, Gong ^a   Barth, Rolf F ^a   Yang, Weilian ^a   Chatterjee, Madhumita ^a   Tjarks, Werner ^a   Ciesielski, Michael J ^b   Fenstermaker, Robert A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BINDING SITES; BORON; BRAIN; CYTOLOGY; DENDRIMERS; ENCODING (SYMBOLS); GENE ENCODING; GENE THERAPY; SIGNAL ENCODING;

BRAIN TUMORS; CETUXIMAB; GENES ENCODING; INTRATUMORAL INJECTION; LOCALISED; NEUTRON CAPTURE THERAPY; RECEPTOR SITES; SITE-SPECIFIC; SPECIFIC CONJUGATIONS; WILD-TYPE CELLS;

TUMORS;

3 (2 PYRIDYLDITHIO)PROPIONIC ACID N HYDROXYSUCCINIMIDE ESTER; AMINE; BORON; C225 G5 B 100; CETUXIMAB; DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HYDRAZIDE; MALEIMIDE DERIVATIVE; N (MALEIMIDOUNDECANOIC ACID) HYDRAZIDE; OLIGOSACCHARIDE; POLYAMIDOAMINE; PROPIONIC ACID DERIVATIVE; REAGENT; SUCCINIC ACID DERIVATIVE; THIOACETAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY COMBINING SITE; ARTICLE; CELL STRAIN F98; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG IMPLANT; DRUG TARGETING; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOMA CELL; NEUTRON CAPTURE THERAPY; NONHUMAN; RADIOASSAY; RAT; STOICHIOMETRY;

ANIMALIA;

EID: 0842285204     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0341674     Document Type: Article

References (70)

1. Davis, F. G., Freeks, S., Grutsch, J., Barlas, S., and Brem, S. (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: and analysis based on surveillance, epidemiology and end results (SEER) data 1973-1991. J. Neurosurg. 88, 1-10.
2. Gutin, P. H., and Posner, J. B. (2000) Neuro-oncology: Diagnosis and management of cerebral gliomas - past, present, and future. Neurosurgery 47, 1-8.
3. Mischel, P. S., Cloughesy, T. F. (2003) Targeted molecular therapy of GBM. Brain Pathol. 13, 52-61.
4. Tremont-Lukats, I. W., and Gilbert, M. R. (2003) Advances in molecular therapies in patients with brain tumors. Cancer Control 10, 125-137.
5. Sauter, G., Maeda, T., Waldman, F. M., Davis, R. L., and Feuerstein, B. G. (1996) Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am. J. Pathol. 148, 1047-1053.
6. Schwechheimer, K., Huang, S., and Cavenee, W. K. (1995) EGFR gene amplification-rearrangement in human glioblastoma. Int. J. Cancer 62, 145-148.
7. Bonomi, P. (2003) Clinical studies with non-Iressa EGFR tyrosine kinase inhibitors. Lung Cancer 41, Suppl 1: S43-48.
8. Anido, J., Matar, P., Albanell, J., Guzman, M., Rojo, F., Arribas, J., Averbuch, S., and Baselga, J. (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/ HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 9, 1274-1283.
9. Grunwald, V., and Hidalgo, M. (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. 95, 851-67.
10. Ciardiello, F. (2000) Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 62, Suppl 1, 25-32.
11. Modjtahedi, H., Hickish, T., Nicolson, M., Moore, J., Styles, J., Exxles, S., Jackson, E., Salter, J., Sloane, J., Spencer, L., Priest, K., Smith, I., Dean, C., and Gore, M. (1996) A phase I trial and tumour localisation of the anti-EGFR antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 73, 228-235.
12. Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., and Jakabovits, A. (1999) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236.
13. Wikstrand, C. J., Cokgor, I., Sampson, J. H., and Bigner, D. D. (1999) Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev. 18, 451-64.
14. Nagane, M., Lin, H., Cavenee, W. K., and Huang, H. J. (2001) Aberrant receptor signaling in human malignant gliomas: Mechanisms and therapeutic implications. Cancer Letter 162, Suppl, S17-S21.
15. Arteaga, C. L. (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 29, Suppl 14, 3-9.
16. Mendelsohn, J. (2002) Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20, 1s-13s.
17. Huang, S. M., Bock, J. M., and Harari, P. M. (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59, 1935-1940.
18. Milas, L., Mason, K., Hunter, N., Petersen, S., Yamakawa, M., Ang, K., Mendelsohn, J., and Fan, Z. (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 6, 701-708.
19. Needle, M. N. (2002) Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin. Oncol. 29, 55-60.
20. Bianco, C., Bianco, R., Tortora, G., Damiano, V., Guerrieri, P., Montemaggi, P., Mendelsohn, J., De Placido, S., Bianco, A. R., and Ciardiello, F. (2000) Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type 1 protein kinase A antisense oligonucleotide. Clin. Cancer Res. 6, 4343-4350.
21. Harari, P. M., and Huang, S. M. (2002) Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int. J. Radiat. Oncol. Phys. 49, 427-433.
22. Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J., Wu, J. Y., Zhang, P., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J., Clayman, G., Pfister, D., Falcey, J., Waksal, H., Mendelsohn, J., and Hong, W. K. (2001) Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7, 1204-1213.
23. Vega, J., Ke, S., Fan, Z., Wallace, S., Charsangavej, C., and Li, C. (2003) Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a poly(ethylene glycol) spacer. Pharm. Res. 20, 826-832.
24. Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., and Radinsky, R. (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 6, 1936-1948.
25. Herbst, R. S., and Langer, C. J. (2002) Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 29, 27-36.
26. Barth, R. F., Adams, D. M., Soloway, A. H., Alam, F., and Darby, M. V. (1994) Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjugate Chem. 5, 58-66.
27. Liu, L., Barth, R. F., Adams, D., Soloway, A. H., and Reisfeld, R. A. (1995) Bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. J. Hematother. 4, 477-483.
28. Liu, L., Barth, R. F., Adams, D. M., Soloway, A. H. and Reisfeld, R. A. (1996): Critical evaluation of bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors. Anticancer Res. 16, 2581-2588.
29. Capala, J., Barth, R. F., Bendayan, M., Lauzon, M., Adams, D. M., Soloway, A. H., Fenstermaker, R. A., and Carlsson, J. (1996) Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy of brain tumors. Bioconjugate Chem. 7, 7-15.
30. Carlsson, J., Gedda, L., Grönvik, C., Hartman, T., Lindström, A., Lindström, P., Lundqvist, H., Lövqvist, A., Malmqvist, J., Olsson, P., Essand, M., Pontén, J., Sjöberg, S., Westermark, B. (1994) Strategy for boron neutron capture therapy against tumor cells with overexpression of the epidermal growth factor receptor. Int. J. Radiat. Oncol. Biol. Phys. 30, 105-115.
31. Olsson, P., Gedda, L., Goike, H., Liu, L., Collins, V. P., Pontén, J., and Carlsson, J. (1998) Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without homan EGF-receptor expression. Anticancer Drug Des. 13, 279-289.
32. Carlsson, J., Kullberg, E. B., Capala, J., Sjöberg, S., Edwards, K., and Gedda, L. (2003) Ligand liposomes and boron neutron capture therapy. J. Neuro-Oncology 62, 47-59.
33. Soloway, A. H., Tjarks, W., Barnum, B. A., Rong, F.-G., Barth, R. F., Codogni, I. M., and Wilson, J. G. (1998) The chemistry of neutron capture therapy. Chem. Rev. 98, 1515-1562.
34. Barth, R. F., Soloway, A. H., Goodman, J. H., Gahbauer, R. E., Gupta, N., Blue, T. E., Yang, W., and Tjarks, W. (1999) Boron neutron capture therapy of brain tumors: an emerging therapeutic modality. Neurosurgery 44, 433-451.
35. Coderre, J. A., and Morris, G. M. (1999) The radiation biology of boron neutron capture therapy. Radiat. Res. 151, 1-18.
36. Sauerwein, W., Moss, R., and Wittig, A., Eds. (2002) Research and development in neutron capture therapy, Monduzzi Editore S.p. A., International Proceedings Division, Bologna, Italy.
37. Barth, R. F. (2003) A critical assessment of boron neutron capture therapy: An overview. J. Neuro-Oncol. 62, 1-5.
38. Barth, R. F., Yang, W., Adams, D. M., Rotaru, J. H., Shukla, S., Sekido, M., Tjarks, W. Fenstermaker, R. A., Ciesielski, M., Nawrocky, M. M., and Coderre, J. A. (2002) Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62, 3159-3166.
39. Shukla, S., Wu, G., Chatterjee, M., Yang, W., Sekido, M., Diop, L. A., Muller, R., Sudimack, J. J., Lee, R. J., Barth, R. F., and Tjarks, W. (2003) Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjugate Chem. 14, 158-167.
40. Barth, R. F., Adams, D. M., Soloway, A. H., Mechetner, E. B., Alam, F., and Anisuzzaman, A. K. (1991) Determination of boron in tissues and cells using direct-current plasma atomic emission spectroscopy. Anal. Chem. 63, 890-893.
41. Barth, R. F., Yang, W., and Coderre, J. A. (2003) Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation. J. Neuro-Oncol. 62, 61-74.
42. Reist, C. J., Garg, P. K., Alston, K. L., Bigner, D. D., and Zalutsky, M. R. (1996) Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. 56, 4970-4977.
43. Novick, S., Quastel, M. R., Marcus, S., Chipman, D., Shani, G., Barth, R. F., and Soloway, A. H. (2002) Linkage of boronated polylysine to glycoside moieties of polyclonal antibody; boronated antibodies as potential delivery agents for neutron capture therapy. Nucl. Med. Biol. 29, 159-67.
44. Yang, W., Barth, R. F., Adams, D. M., and Soloway, A. H. (1997) Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res. 57, 4333-4339.
45. Esfand, R., and Tomalia, D. A. (2001) Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 6, 427-436.
46. Chow, H.-F., Mong, T. K. K., Nongrum, M. F., and Wan, C.-W. (1998) The synthesis and properties of novel functional dendritic molecules. Tetrahedron 54, 8543-8660.
47. Quintana, A., Raczka, E., Piehler, L., Lee, I., Myc, A., Majoros, I., Patri, A. K., Thomas, T., Mulé, J., and Baker, Jr. J. R. (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19, 1310-1316.
48. Zhou, R. X., Du, B., and Lu, Z. R. (1999) In vitro release of 5-flourouracil with cyclic core dendritic polymer. J. Controlled Resease 57, 249-257.
49. Kobayashi, H., Wu, C., Kim, M. K., Paik, C. H., Carrasquillo, J. A., and Brechbiel, M. W. (1999) Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody. Bioconjugate Chem. 11, 103-111.
50. Kobayashi, H., Sato, N., Saga, T., Nakamoto, Y., Ishimori, T., Toyama, S., Togashi, K., Konishi, J., and Brechbiel, M. W. (2000) Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur. J. Nucl. Med. 27, 1334-1339.
51. Kobayashi, H., Kawamoto, S., Saga, T., Sato, N., Ishimori, T., Konishi, J., Ono, K., Togashi, K., and Brechbiel, M. W. (2001) Avidin-dendrimer-(1B4M-Gd)254: A tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjugate Chem. 12, 587-593.
52. Safavy, A., Bonner, J. A., Waksal, H. W., Buchbaum, D. J., Gillespie, G. Y., Khazaeli, M. B., Arani, R., Chen, D.-T., Carpenter, M., and Raisch, K. P. (2003) Synthesis and biological evaluation of paclitaxel-c225 conjugate as a model for targeted drug delivery. Bioconjugate Chem. 14, 302-310.
53. Wen, X., Wu, Q.-P., Lu, Y., Fan, Z., Charnsagavej, C., Wallace, S., Chow, D., and Li, Ch. (2001) Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. Bioconjugate Chem 12, 545-553.
54. Snelling, L., Miyamoto, C. T., Bender, J., Brady, L. W., Stepewski, Z., Class, R., Emrich, J., and Rackover, M. A. (1995) Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 14, 111-114.
55. Faillot, T., Magdelenat, H., Mady, E., Stasiecki, P., Fohanno, D., Gropp, P., Poisson, M., and Delattre, J. Y. (1996) A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 39, 478-483.
56. Greig, N. H. (1994) Drug delivery to the brain by blood-brain barrier circumvention and drug modification, in Implication of the blood-brain barrier and its manipulation (E. A. Neuwelt, Ed.) Vol. 1, pp 311-367, Plenum Press, New York.
57. Yang, W., Barth, R. F., Adams, D. M., and Soloway, A. H. (1997) Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res. 57, 4333-4339.
58. Yang, W., Barth, R. F., Leveille, R., Adams, D. M., Capala, J., Ciesielski, M., and Fenstermaker, R. A. (2001) Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent. J. Neuro-Oncol. 55, 19-28.
59. Yang, W., Barth, R. F., Adams, D. M., Ciesielski, M. J., Fenstermaker, R. A., Shukla, S., Tjarks, W., and Caliguri, M. A. (2002) Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62, 6552-6558.
60. Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., and Oldfield, E. H. (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J. Neurosurg. 82, 1021-1029.
61. Laske, D. W., Youle, R. J., Morrison, P. F., Governale, L. S., and Oldfield, E. H. (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med. 3, 1362-1368.
62. Groothuis, D. R., Ward, S., Itskovich, A. C., Dobrescu, C., Allen, C. V., Dills, C., and Levy, R. M. (1999) Comparison of 14C-sucrose delivery to brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J. Neurosurg. 90, 321-331.
63. Yang, W., Barth, R. F., Adams, D. M., Fenstermaker, R. A., Ciesielski, M. J., Shukla, S., Sekido, M., Tjarks, W., and Wikstrand, C. J. (2002) Molecular targeting of EGFRvIII positive gliomas: Convection enhanced delivery vs intratumoral injection of boronated monoclonal antibody L8A4, in Research and Development in Neutron Capture Therapy. (W. Sauerwein, R. Moss, and A. Wittig, Eds.) Monduzzi Editore S.p. A., pp 841-844, International Proceedings Division, Bologna, Italy.
64. Kuan, C. T., Wikstrand, C. J., and Bigner, D. D. (2001) EGF mutant receptor VIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8, 83-96.
65. Pederson, M. W., Meltorn, M., Damstrup, L., and Poulsen, H. S. (2001) The type III epidermal growth factor receptor mutation. Biological significance and potential target for anticancer therapy. Ann. Oncol. 12, 745-760.
66. Diaz, A. Z. (2003) Assessment of the results from the Phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J. Neuro-Oncol. 62, 101-109.
67. Busse, P. M., Harling, O. K., Palmer, M. R., Kiger, W. S., Kaplan, J., Kaplan, I., Chuang, C. F., Goorley, J. T., Riley, K. J., Newton, T. H., Santa Cruz, G. A., Lu, X.-Q., and Zamenhof, R. G. (2003) A critical examination of the results from the Harvard-MIT NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J. Neuro-Oncol. 62, 111-121.
68. Joensuu, H., Kankaanranta, L., Seppälä, T., Auterinen, I., Kallio, M., Kulvik, M., Laakso, J., Vähütalo, J., Kortesniemi, M., Kotilutot, P., Serén, T., Karila, J., Brander, A., Järviluoma, E., Ryynänen, P., Paetau, A., Ruokonen, I., Minn, H., Tenhunen, M., Jääskeläinen, J., Färkkilä, M., and Savolainen, S. (2003) Boron neutron capture therapy of brain tumors: Clinical trials at the Finnish facility using boronophenylalanine. J. Neuro-Oncol. 62, 123-134.
69. Capala, J., H.-Stensam, B., Sköld, K., af Rosenschöld, P. M., Giusti, V., Persson, C., Wallin, E., Brun, A., Franzen, L., Carlsson, J., Salford, L., Ceberg, C., Persson, B., Oerittieli, L., and Henriksson, R. (2003) Boron neutron capture therapy for glioblastoma multiforme: Clinical studies in Sweden. J. Neuro-Oncol. 62, 135-144.
70. Nakagawa, Y., Pooh, K., Kobayashi, T., Sakurai, Y., Kageji, T., Uyama, S., Matsumura, A., Yamamoto, T., and Kumada, H. (2003) Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J. Neuro-Oncol. 62, 87-99.